171 related articles for article (PubMed ID: 21858040)
1. Comparison of the safety and pharmacokinetics of ST-246® after i.v. infusion or oral administration in mice, rabbits and monkeys.
Chen Y; Amantana A; Tyavanagimatt SR; Zima D; Yan XS; Kasi G; Weeks M; Stone MA; Weimers WC; Samuel P; Tan Y; Jones KF; Lee DR; Kickner SS; Saville BM; Lauzon M; McIntyre A; Honeychurch KM; Jordan R; Hruby DE; Leeds JM
PLoS One; 2011; 6(8):e23237. PubMed ID: 21858040
[TBL] [Abstract][Full Text] [Related]
2. Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
Jordan R; Chinsangaram J; Bolken TC; Tyavanagimatt SR; Tien D; Jones KF; Frimm A; Corrado ML; Pickens M; Landis P; Clarke J; Marbury TC; Hruby DE
Antimicrob Agents Chemother; 2010 Jun; 54(6):2560-6. PubMed ID: 20385870
[TBL] [Abstract][Full Text] [Related]
3. Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers.
Chinsangaram J; Honeychurch KM; Tyavanagimatt SR; Leeds JM; Bolken TC; Jones KF; Jordan R; Marbury T; Ruckle J; Mee-Lee D; Ross E; Lichtenstein I; Pickens M; Corrado M; Clarke JM; Frimm AM; Hruby DE
Antimicrob Agents Chemother; 2012 Sep; 56(9):4900-5. PubMed ID: 22777041
[TBL] [Abstract][Full Text] [Related]
4. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
Jordan R; Tien D; Bolken TC; Jones KF; Tyavanagimatt SR; Strasser J; Frimm A; Corrado ML; Strome PG; Hruby DE
Antimicrob Agents Chemother; 2008 May; 52(5):1721-7. PubMed ID: 18316519
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and interspecies allometric scaling of ST-246, an oral antiviral therapeutic for treatment of orthopoxvirus infection.
Amantana A; Chen Y; Tyavanagimatt SR; Jones KF; Jordan R; Chinsangaram J; Bolken TC; Leeds JM; Hruby DE
PLoS One; 2013; 8(4):e61514. PubMed ID: 23637845
[TBL] [Abstract][Full Text] [Related]
6. Oral Tecovirimat for the Treatment of Smallpox.
Grosenbach DW; Honeychurch K; Rose EA; Chinsangaram J; Frimm A; Maiti B; Lovejoy C; Meara I; Long P; Hruby DE
N Engl J Med; 2018 Jul; 379(1):44-53. PubMed ID: 29972742
[TBL] [Abstract][Full Text] [Related]
7. Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs.
Supko JG; Garcia-Carbonero R; Puchalski TA; Malspeis L
Cancer Chemother Pharmacol; 2001 Sep; 48(3):202-8. PubMed ID: 11592341
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic comparison of a single oral dose of polymorph form i versus form V capsules of the antiorthopoxvirus compound ST-246 in human volunteers.
Chinsangaram J; Honeychurch KM; Tyavanagimatt SR; Bolken TC; Jordan R; Jones KF; Marbury T; Lichtenstein I; Pickens M; Corrado M; Landis P; Clarke JM; Frimm AM; Hruby DE
Antimicrob Agents Chemother; 2012 Jul; 56(7):3582-6. PubMed ID: 22526314
[TBL] [Abstract][Full Text] [Related]
9. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
Jordan R; Goff A; Frimm A; Corrado ML; Hensley LE; Byrd CM; Mucker E; Shamblin J; Bolken TC; Wlazlowski C; Johnson W; Chapman J; Twenhafel N; Tyavanagimatt S; Amantana A; Chinsangaram J; Hruby DE; Huggins J
Antimicrob Agents Chemother; 2009 May; 53(5):1817-22. PubMed ID: 19223621
[TBL] [Abstract][Full Text] [Related]
10. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
11. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of ethylene glycol. III. Plasma disposition and metabolic fate after single increasing intravenous, peroral, or percutaneous doses in the male Sprague-Dawley rat.
Frantz SW; Beskitt JL; Tallant MJ; Zourelias LA; Ballantyne B
Xenobiotica; 1996 May; 26(5):515-39. PubMed ID: 8736063
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
Retlich S; Duval V; Ring A; Staab A; Hüttner S; Jungnik A; Jaehde U; Dugi KA; Graefe-Mody U
Clin Pharmacokinet; 2010 Dec; 49(12):829-40. PubMed ID: 21053992
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys.
Nomeir AA; Kumari P; Hilbert MJ; Gupta S; Loebenberg D; Cacciapuoti A; Hare R; Miller GH; Lin CC; Cayen MN
Antimicrob Agents Chemother; 2000 Mar; 44(3):727-31. PubMed ID: 10681346
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and tolerability of oral iloprost in thromboangiitis obliterans patients.
Hildebrand M
Eur J Clin Pharmacol; 1997; 53(1):51-6. PubMed ID: 9349930
[TBL] [Abstract][Full Text] [Related]
16. Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents.
Ananthula HK; Parker S; Touchette E; Buller RM; Patel G; Kalman D; Salzer JS; Gallardo-Romero N; Olson V; Damon IK; Moir-Savitz T; Sallans L; Werner MH; Sherwin CM; Desai PB
BMC Pharmacol Toxicol; 2018 Dec; 19(1):80. PubMed ID: 30514402
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of michellamine B, a naphthylisoquinoline alkaloid with in vitro activity against human immunodeficiency virus types 1 and 2, in the mouse and dog.
Supko JG; Malspeis L
Antimicrob Agents Chemother; 1995 Jan; 39(1):9-14. PubMed ID: 7695336
[TBL] [Abstract][Full Text] [Related]
18. Effects of formulation and route of administration on the systemic availability of Ex-RAD®, a new radioprotectant, in preclinical species.
Chun AW; Freshwater RE; Taft DR; Gillum AM; Maniar M
Biopharm Drug Dispos; 2011 Mar; 32(2):99-111. PubMed ID: 21341279
[TBL] [Abstract][Full Text] [Related]
19. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers.
Schmitt-Hoffmann A; Roos B; Heep M; Schleimer M; Weidekamm E; Brown T; Roehrle M; Beglinger C
Antimicrob Agents Chemother; 2006 Jan; 50(1):279-85. PubMed ID: 16377698
[TBL] [Abstract][Full Text] [Related]
20. Tecovirimat: First Global Approval.
Hoy SM
Drugs; 2018 Sep; 78(13):1377-1382. PubMed ID: 30120738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
